New Genetic Engineering – Small Cause, Big Effect
By Benedikt Haerlin,
ARC2020
| 07. 07. 2023
Adding, removing or swapping individual base pairs in the genome can make a huge difference to the functioning of a cell and the properties of an entire organism. It’s a bit like Johann Sebastian Bach’s definition of skilful piano playing: you just have to press the right key at the right time. It’s that simple, and yet also that difficult. Therein lies the appeal of genetic engineering, but also its risk.
The European Commission is now proposing that plants that have been genetically modified at up to twenty different sites of the genome should nevertheless be “considered equivalent to conventional plants”. At these twenty sites, any number of base pairs (nucleotides) may be deleted or inverted, up to 20 base pairs may be completely altered or replaced, any length of contigous DNA sequences may be replaced by related sequences, and any other alteration of any kind may be made that already occurs in any plant that can be crossed directly with the genetically modified plant or via intermediate steps.
No individual risk assessment and approval would be required for those...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...